Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2008

View Archived Issues

GDC-0449 shows safety and good PK profile in patients with advanced solid cancers

CuraGen reports results from phase I/II study of CR011-vcMMAE

Preclinical evaluation of novel gene therapy for the treatment of hereditary inclusion-body myositis

JNK inhibition shows benefit in experimental endometriosis

Novartis presents update on pipeline of novel vaccine candidates

First phase I clinical results for JM-1232 reported

TorreyPines initiates phase I clinical trial for oral prodrug of tezampanel

Positive opinion issued to broaden use of Erbitux, including first-line colorectal cancer

Indevus presents update on NDA for Nebido

Achillion nominates ACH-1625 as first clinical candidate in HCV protease program

Nuvelo initiates enrollment in phase Ib trial of bolus plus infusion dosing of NU-172

Nine European countries grant national marketing authorizations to SpePharm's Loramyc

Transcept to submit NDA to FDA for Intermezzo in the third quarter of 2008

Medicago reports positive results from preclinical study in ferrets of H5N1 VLP vaccine

Ipsen to acquire Tercica

FDA approves Angioblast's IND application to initiate phase II trial of allogeneic stem cells

Intercytex completes enrollment in phase III trial of Cyzact in venous leg ulcers

Arana successfully engineers second candidate antibody under collaboration with CSL

Merck Serono and ZymoGenetics initiate phase II/III trial of atacicept in SLE

Epix identifies three lead candidates in third G-protein-coupled receptor discovery program

CHMP recommends refusing Takeda's MAA for ramelteon

PharmaGap's PhG-alpha-1 reduces tumor size, increases survival in colon cancer models

Recent Devgen patent discloses novel agents for glaucoma

Novel antiinflammatory agents disclosed in recent patent literature

Recent Roche patent reports new therapeutic agents for urological disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...